Global Breast Implants market size was valued at USD 1010 million in 2021 and is anticipated to grow at USD 2191 million till 2028 recording a CAGR of 11.7.% during the forecast period 2022-2028. Breast implants are the medical devices, used in the post-mastectomy to improve the aesthetic appeal. Breast implants are made up of a silicone outer shell and a filler such as silicone gel or saline. Breast implantation can be done by reconstructive plastic surgery or surgical practice. In reconstructive surgery process, the implants are inserted to correct deformities and congenital defects of the chest wall and also used to restore a natural appearance of a breast mound of post-mastectomy breast reconstruction patients. In surgical practice, tissue expander devices are used as temporary breast prosthesis to establish and form an implant pocket for the administration of permanent breast implants. In males, pectoral implants are used as a prosthesis for the aesthetic repair and reconstruction of the chest wall to correct the deformities and defects in the chest. For instance, in February 2013, FDA approved a silicone gel-filled breast implant manufactured by Allergan Plc, which uses more cohesive silicone gel, compared with previously approved breast implants. Similarly, In June 2013, the U.S. FDA has approved a silicone gel-filled breast implant which uses a more cohesive silicone gel manufactured by Mentor’s PMA, compared with their previously approved breast implants. Moreover, acquisitions and mergers, collaborations, and key licensing agreements also bolster the market growth. For instance, in December 2008, Johnson & Johnson has acquired breast-implant maker Mentor Corporation for the manufacturing of breast implants. In March 2015, Actavis plc has acquired of Allergan, Inc. to manufacture breast implants. Geographically, the breast implants market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. In January 2016, Allergan plc received approval from the U.S. Food and Drug Administration (FDA) to market   Natrelle Inspira Soft touch breast implants. In June 2016, Establishment labs received approval from the Korean Food & Drug Administration (KFDA) for Motiva Implants.



Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072


Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX